Terms: = Ovarian cancer AND ZFHX3, ATBT, 463, ENSG00000140836, Q15911 AND Treatment
21 results:
1. A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.
Komatsu H; Matsumoto K; Morita M; Nagasawa T; Nishio H; Suzuki J; Nishio S; Kobara H; Yunokawa M; Ariyoshi K; Hirayama T; Tokunaga H; Ukita M; Yoriki K; Mori-Uchino M; Furusawa A; Togami S; Nakamura H; Ishikawa M; Satoh T
Cancer Med; 2024 Mar; 13(5):e6968. PubMed ID: 38491829
[TBL] [Abstract] [Full Text] [Related]
2. Disparities in refusal of surgery for gynecologic cancer.
Samuel D; Kwon D; Huang M; Zhao W; Roy M; Tabuyo-Martin A; Siemon J; Schlumbrecht MP; Pearson JM; Sinno AK
Gynecol Oncol; 2023 Jul; 174():1-10. PubMed ID: 37141816
[TBL] [Abstract] [Full Text] [Related]
3. Is complete mesocolic excision or total mesorectal excision necessary during cytoreductive surgery in ovarian peritoneal carcinomatosis with colonic involvement?
Karadayi K; Karabacak U
Acta Chir Belg; 2023 Apr; 123(2):124-131. PubMed ID: 34253150
[TBL] [Abstract] [Full Text] [Related]
4. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
Kato I; Kasukabe T; Kumakura S
Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
[TBL] [Abstract] [Full Text] [Related]
5. Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Tanabe Y; Shiraishi S; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y; Shimizu C
BMC Cancer; 2020 Apr; 20(1):325. PubMed ID: 32295642
[TBL] [Abstract] [Full Text] [Related]
6. SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression.
Liao YM; Song Y; Li YK; Du JH; Zhou Y
Cancer Gene Ther; 2020 Apr; 27(3-4):256-263. PubMed ID: 31543512
[TBL] [Abstract] [Full Text] [Related]
7. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract] [Full Text] [Related]
8. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.
Zhang L; Luo M; Yang H; Zhu S; Cheng X; Qing C
J Ovarian Res; 2019 Feb; 12(1):19. PubMed ID: 30786925
[TBL] [Abstract] [Full Text] [Related]
9. Adjuvant Therapy Use and Survival in Stage II Endometrial cancer.
Lester-Coll NH; Young MR; Park HS; Ratner ES; Litkouhi B; Damast S
Int J Gynecol Cancer; 2017 Nov; 27(9):1904-1911. PubMed ID: 28763364
[TBL] [Abstract] [Full Text] [Related]
10. Application of sentinel lymph node dissection in gynecological cancers: results of a survey among German hospitals.
Klapdor R; Hertel H; Soergel P; Jentschke M; Hillemanns P
Arch Gynecol Obstet; 2017 Mar; 295(3):713-720. PubMed ID: 28035487
[TBL] [Abstract] [Full Text] [Related]
11. Reduced ovarian cancer Incidence in Women Exposed to Low Dose Ionizing Background Radiation or Radiation to the Ovaries after treatment for Breast cancer or Rectosigmoid cancer.
Lehrer S; Green S; Rosenzweig KE
Asian Pac J Cancer Prev; 2016; 17(6):2979-82. PubMed ID: 27356721
[TBL] [Abstract] [Full Text] [Related]
12. The effect of chemotherapy-induced anemia on dose reduction and dose delay.
Family L; Xu L; Xu H; Cannavale K; Sattayapiwat O; Page JH; Bohac C; Chao C
Support Care Cancer; 2016 Oct; 24(10):4263-71. PubMed ID: 27167627
[TBL] [Abstract] [Full Text] [Related]
13. [Histological subtypes of ovarian carcinoma and their importance for clinical prognosis].
Zlatkov V
Akush Ginekol (Sofiia); 2015; 54(2):19-23. PubMed ID: 25909136
[TBL] [Abstract] [Full Text] [Related]
14. 18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation.
Kuyumcuoğlu U; Guzel AI; Celik Y; Erdemoğlu M; Komek H
Ginekol Pol; 2011 Aug; 82(8):602-6. PubMed ID: 21957605
[TBL] [Abstract] [Full Text] [Related]
15. Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.
Kwon YS; Nam JH; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
J Korean Med Sci; 2009 Aug; 24(4):679-83. PubMed ID: 19654952
[TBL] [Abstract] [Full Text] [Related]
16. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract] [Full Text] [Related]
17. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
[TBL] [Abstract] [Full Text] [Related]
18. [Laparoscopic management of occult cervical cancer discovered after simple hysterectomy].
Vignancour S; Narducci F; Collinet P; Vinatier D; Castelain B; Leblanc E
Gynecol Obstet Fertil; 2007 Apr; 35(4):297-302. PubMed ID: 17337353
[TBL] [Abstract] [Full Text] [Related]
19. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population.
Lambert HE; Gregory WM; Nelstrop AE; Rustin GJ
Int J Gynecol Cancer; 2004; 14(5):772-8. PubMed ID: 15361183
[TBL] [Abstract] [Full Text] [Related]
20. The International (Ludwig) Breast cancer Study Group Trials I-IV: 15 years follow-up.
Castiglione-Gertsch M; Johnsen C; Goldhirsch A; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Hacking A; Cortes-Funes H; Forbes J
Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
[TBL] [Abstract] [Full Text] [Related]
[Next]
